Morcos A, Jung Y, Galvan Bustillos J, Fuller R, Caba Molina D, Bertucci A
Cancers (Basel). 2024; 16(19).
PMID: 39409913
PMC: 11475672.
DOI: 10.3390/cancers16193293.
Mhetre A, Sreedhar E, Dubey R, Sable G, Lee H, Yang H
RSC Adv. 2022; 9(50):29023-29036.
PMID: 35528410
PMC: 9071829.
DOI: 10.1039/c9ra04749b.
Mullins E, Dorival J, Tang G, Boger D, Eichman B
Nat Commun. 2021; 12(1):6942.
PMID: 34836957
PMC: 8626424.
DOI: 10.1038/s41467-021-27284-7.
Mullins E, Shi R, Eichman B
Nat Chem Biol. 2017; 13(9):1002-1008.
PMID: 28759018
PMC: 5657529.
DOI: 10.1038/nchembio.2439.
Savreux-Lenglet G, Depauw S, David-Cordonnier M
Int J Mol Sci. 2015; 16(11):26555-81.
PMID: 26556350
PMC: 4661830.
DOI: 10.3390/ijms161125971.
Anticancer potential of Conium maculatum extract against cancer cells in vitro: Drug-DNA interaction and its ability to induce apoptosis through ROS generation.
Mondal J, Panigrahi A, Khuda-Bukhsh A
Pharmacogn Mag. 2014; 10(Suppl 3):S524-33.
PMID: 25298670
PMC: 4189268.
DOI: 10.4103/0973-1296.139792.
Pyrrolo(l ,4)benzodiazepine Antitumor Antibiotics: Chemistry, Interaction with DNA, and Biological Implications.
Hurley L, Thurston D
Pharm Res. 2013; 1(2):52-9.
PMID: 24277212
DOI: 10.1023/A:1016395113085.
Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction.
Bishayee K, Ghosh S, Mukherjee A, Sadhukhan R, Mondal J, Khuda-Bukhsh A
Cell Prolif. 2013; 46(2):153-63.
PMID: 23510470
PMC: 6495502.
DOI: 10.1111/cpr.12017.
Replication fork stalling by bulky DNA damage: localization at active origins and checkpoint modulation.
Minca E, Kowalski D
Nucleic Acids Res. 2010; 39(7):2610-23.
PMID: 21138968
PMC: 3074140.
DOI: 10.1093/nar/gkq1215.
Multiple Rad5 activities mediate sister chromatid recombination to bypass DNA damage at stalled replication forks.
Minca E, Kowalski D
Mol Cell. 2010; 38(5):649-61.
PMID: 20541998
PMC: 2887677.
DOI: 10.1016/j.molcel.2010.03.020.
Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.
Tichenor M, Trzupek J, Kastrinsky D, Shiga F, Hwang I, Boger D
J Am Chem Soc. 2006; 128(49):15683-96.
PMID: 17147378
PMC: 2515590.
DOI: 10.1021/ja064228j.
Synthesis and cytotoxicity of a biotinylated CC-1065 analogue.
Wang Y, Yuan H, Wright S, Wang H, Larrick J
BMC Chem Biol. 2002; 2(1):1.
PMID: 11846891
PMC: 65513.
DOI: 10.1186/1472-6769-2-1.
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
Foster B, LoRusso P, Poplin E, Zalupski M, Valdivieso M, Wozniak A
Invest New Drugs. 1996; 13(4):321-6.
PMID: 8824350
DOI: 10.1007/BF00873138.
A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells.
Ogasawara H, Nishio K, Takeda Y, Ohmori T, Kubota N, Funayama Y
Jpn J Cancer Res. 1994; 85(4):418-25.
PMID: 8200853
PMC: 5919473.
DOI: 10.1111/j.1349-7006.1994.tb02375.x.
Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Smith K, Folz B, Adams E, Bhuyan B
Cancer Chemother Pharmacol. 1995; 35(6):471-82.
PMID: 7533669
DOI: 10.1007/BF00686831.
V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.
Butryn R, Smith K, Adams E, Abraham I, Stackpole J, Sampson K
Cancer Chemother Pharmacol. 1994; 34(1):44-50.
PMID: 7513620
DOI: 10.1007/BF00686110.
Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.
Hurley L, Reynolds V, Theriault N, KRUEGER W, Wierenga W
Nucleic Acids Res. 1984; 12(15):6159-68.
PMID: 6473105
PMC: 320064.
DOI: 10.1093/nar/12.15.6159.
Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.
Zakrzewska K, Randrianarivelo M, PULLMAN B
Nucleic Acids Res. 1987; 15(14):5775-85.
PMID: 3615201
PMC: 306022.
DOI: 10.1093/nar/15.14.5775.
Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.
Li L, Kelly R, Warpehoski M, McGovren J, Gebhard I, DeKoning T
Invest New Drugs. 1991; 9(2):137-48.
PMID: 1874598
DOI: 10.1007/BF00175081.
Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.
Nguyen H, Sevin B, Averette H, Perras J, Ramos R, Donato D
J Cancer Res Clin Oncol. 1992; 118(7):515-22.
PMID: 1624543
DOI: 10.1007/BF01225266.